Edition:
United States

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.79USD
17 Oct 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.79
Open
$1.83
Day's High
$1.84
Day's Low
$1.73
Volume
100,696
Avg. Vol
71,529
52-wk High
$2.01
52-wk Low
$1.04

Chart for

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.13
Market Cap(Mil.): $174.48
Shares Outstanding(Mil.): 97.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 91.69 16.82
EPS (TTM): -- -- --
ROI: -- 2.46 11.24
ROE: -- 3.30 15.07

BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

Sep 26 2017

BRIEF-U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia

* U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli)

Sep 18 2017

BRIEF-Pluristem Therapeutics awarded two new patents in Hong Kong

* Awarded two new patents in Hong Kong for critical limb ischemia and muscle regeneration

Sep 13 2017

BRIEF-U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project

* U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure

Aug 16 2017

BRIEF-Pluristem's ‍ARS study's new data shows hematological deficiencies even at low radiation levels​

* New data from ARS study shows significant hematological deficiencies even at low radiation levels; PLX-R18 supports hematological recovery​ Source text for Eikon: Further company coverage:

Jul 26 2017

BRIEF-Pluristem advances its limb ischemia study, targeting initiation at 40 active sites by the year end

* Pluristem advances its multinational phase III critical limb ischemia study, targeting initiation at 40 active sites by the end of 2017

Jul 10 2017

BRIEF-Pluristem Therapeutics files for mixed shelf of up to $200 mln - SEC Filing

* Pluristem Therapeutics Inc files for mixed shelf of up to $200 million - SEC Filing Source text: [http://bit.ly/2rJWJrh] Further company coverage:

Jun 23 2017

BRIEF-Innovation Medical Management scraps plan to invest in Israel's Pluristem Therapeutics

* Says it scraps plan to invest in Israel's Pluristem Therapeutics Inc

Jun 20 2017

BRIEF-Pluristem provides shareholder update on corporate, clinical developments

* Pluristem provides shareholder update on corporate and clinical developments

May 22 2017

BRIEF-Pluristem provides results from acute radiation syndrome preclinical study

* Pluristem therapeutics inc- announces promising results from non-human primate pilot study of plx-r18 in acute radiation syndrome

May 03 2017

Earnings vs. Estimates